Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...163164165166167168169170171172173...10651066»
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., pomalidomide / Generic mfg.
    POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1159;    
    Induction chemotherapy using bortezomib, pomalidomide, and dexamethasone is safe and efficacious in newly diagnosed multiple myeloma. Further Phase 3 studies with longer follow-ups are necessary to establish the superiority and survival benefit of the pomalidomide-based regimen for myeloma induction.
  • ||||||||||  Tecvayli (teclistamab) / Genmab, J&J
    AN OUTPATIENT MODEL FOR TECLISTAMAB STEP-UP DOSING ADMINISTRATION  (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1142;    
    Both patients were treated with 1 dose of tocilizumab, and the patient with ICANS also received dexamethasone, with prompt resolution of symptoms. Our outpatient teclistamab administration model with close toxicity monitoring and prompt hospitalization fortoxicity management is safe and feasible in heavily pre-treated RRMM patients and allows significant reduction of inpatient stay, resulting in significant healthcare savings and improvement of patients' experience.
  • ||||||||||  cyclophosphamide / Generic mfg.
    STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1137;    
    Our data show that, after Dara-VTd, a mobilization regimen based on CTX 4 g/m 2 and G-CSF allows the collection of high numbers of CD34+ cells and can be safely administered in the outpatient setting. CTX 4 g/m 2 coupled with on-demand and patient-tailored usage of plerixafor is a valuable approach to achieve an optimal CD34+ cell collection after Dara-containing quadruplets, able to guarantee more than one autologous stem cell transplant and possible stem cell boosts in cases of prolonged cytopenia in subsequent therapies.
  • ||||||||||  talquetamab (JNJ-64407564) / J&J
    COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1133;    
    P1, P1b, P
    CTX 4 g/m 2 coupled with on-demand and patient-tailored usage of plerixafor is a valuable approach to achieve an optimal CD34+ cell collection after Dara-containing quadruplets, able to guarantee more than one autologous stem cell transplant and possible stem cell boosts in cases of prolonged cytopenia in subsequent therapies. An external control arm for MonumenTAL-1 was created from pts who were treated with PC as subsequent therapy after discontinuing study treatment from 4 daratumumab trials (CASTOR [NCT02136134]; DCO: June 2021, POLLUX [NCT02076009]; DCO: Sept 2021, EQUULEUS [NCT01998971]; DCO: 2017
  • ||||||||||  elranatamab (PF-06863135) / Pfizer
    INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1129;    
    P=N/A, P2,
    While there is no standard of care for TCE MM, belantamab mafodotin (belamaf) and selinexor plus dexamethasone (sel-dex) are treatment options. Elranatamab had a significantly higher ORR than belamaf, sel-dex, and real-world PCT in LocoMMotion for patients with TCE MM, demonstrating its clear clinical benefit for this population.
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS, Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
    COMPARISON OF MULTIPLE MYELOMA TREATMENT PATTERNS IN 2022 ACROSS UNITED STATES, SOUTH AMERICA, EUROPE AND ASIA (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1113;    
    In front-line MM (Figure 1), quadruplets were the most common regimen, with D-VTd (Daratumumab [D-] + bortezomib [V] + thalidomide [T] + dexamethasone [d]) predominant in Germany (37.9%), UK (41.6%) and Italy (28.9%), while D-RVd (lenalidomide [R]) most common in France (28.3%). Triplets were the most prevalent regimen in the other countries analyzed, with VCd (cyclophosphamide [C]) most common in Brasil (59.1%) and Mexico (31.1%), VRd/RVd in Spain (36.1%), CRd in US (27.5%) and Japan (17.6%) and VDd (doxorubicin [D]) in China (49.2%)...In 2L MM, D-Rd was the most common regimen in the EU4 (20.2% - 50.9%), D-Vd in Brasil (19.8%) and UK (21.1%), D-Pd (pomalidomide [P]) in Japan (10.1%) and US (15.5%), while carfilzomib [K] regimens were most common in Mexico (KRd) and China (KPd)...Ixazomib [N] triplets were the most frequent 3L choice in UK (NRd: 49.7%) and Japan (PNd: 11.4%), VPd in China (17.5%) while elotuzumab [E] was most prevalent in Italy (EPd: 9.6%)...Contemporary real-world evidence on MM treatment landscape across the world shows that treatment patterns remain heterogeneous across countries, with the heterogeneity increasing from 2L onwards.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., thalidomide / Generic mfg.
    CHARACTERIZATION OF REGULATORY T CELLS IN PATIENTS WITH MULTIPLE MYELOMA (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_1093;    
    We performed single-cell RNA sequencing (scRNA-seq) of sorted CD4 + T cells from BM mononuclear cells (BMMCs) of healthy donor (HD), patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), and MM at diagnosis, and patients with or without minimal residual disease (MRD) after treatment with bortezomib/thalidomide/dexamethasone (VTD). We identified 17 clusters of BM CD4 T cells by scRNA-seq,, which were subdivide into classical CD4 T subsets; na
  • ||||||||||  Promacta (eltrombopag) / Novartis
    ASPECTS OF THE THERAPY SELECTION FOR IMMUNE THROMBOCYTOPENIA IN CHILDREN (Poster area) -  May 12, 2023 - Abstract #EHA2023EHA_872;    
    In the absence of predictors of a chronic course in patients, as well as in children under the age of 3 years,it is advisable to use IVIG as monotherapy or combined with methylprednisolone pulse therapy. It is necessary to use thrombopoietin receptor agonists more widely, as well as interferon medicine in modified doses in steroid- resistant patients, which will allow avoiding splenectomy, which is extremely undesirable in childhood.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Thyroid Metastasis From Non-small Cell Lung Cancer: An Unusual Case Presentation (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2523;    
    Several thyroid lesions representing metastases may go unnoticed because the physician's attention toward lesions at other, more common sites, and detailed thyroid examination can be commonly overlooked. Patients with newly diagnosed malignancies should also be screened for thyroid involvement, including detailed physical, radiographic, and histologic examination of pathologic findings.
  • ||||||||||  thyroxine / Generic mfg., hydrocortisone / Generic mfg.
    High degree AV block and Sinus arrest: cardiovascular manifestations of Myxedema Coma (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2497;    
    Few cases of sinus or cardiac arrest associated to Myxedema coma have been reported in the literature. In this case, the patient developed high-degree AV block with concomitant sinus arrest despite prompt initiation of intravenous thyroid hormone.
  • ||||||||||  Metastatic Choriocarcinoma, A Rare Cause of hCG-Mediated Hyperthyroidism (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2494;    
    Hyperthyroidism in these cases is usually subclinical or mild, but instances of thyroid storm have been reported with metastatic disease. Beta blockers, glucocorticoids, and thionamides can be used as temporizing measures, but definitive therapy requires treatment of the causative malignancy.
  • ||||||||||  acetazolamide / Generic mfg., topiramate / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    A Case of Idiopathic Intracranial Hypertension in Gender Dysphoria: Is Testosterone the Culprit? (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2442;    
    Given the scarcity of evidence, it is important to discuss the potential risk of IIH with transgender patients, but not to withhold gender affirming hormone therapy for these patients. More research is required to better explore the mechanism of this association and possible methods to prevent its occurrence.
  • ||||||||||  dexamethasone / Generic mfg.
    Small Compounds Modulate Glucocorticoid Receptor Function by Binding to a Novel Allosteric Pocket (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2375;    
    Synthetic glucocorticoids, as Dexamethasone, are widely used in the clinic for the treatment of chronic inflammatory diseases...In this work, we present a deep biochemical and biophysical analysis showing how small molecules are able to bind a new allosteric pocket in solution and how these compounds can modulate GR transcriptional activity in cells. These findings can be essential to further understand GR signaling and how to better design synthetic corticosteroids to avoid side effects.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Repatha Induced Thyroid Storm (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2167;    
    By day 9 of therapy, patient was transitioned to methimazole 30mg daily with discontinuation of hydrocortisone and cholestyramine...PCSK9 inhibitor therapy immunological influence on thyroid remains unknown. This case shows the importance of thyroid function test follow up in patients on PCSK9 inhibitor therapy and the possibility of immunological influence on the thyroid.
  • ||||||||||  thyroxine / Generic mfg., hydrocortisone / Generic mfg.
    Not JUST Severe Hypothyroidism: Recognizing Autoimmune Polyglandular Syndrome (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2159;    
    The 3 classic patterns are: Type 1 (most common): younger women, presents with candidiasis, hypoparathyroidism, and Addison's disease. Type 2: middle-aged women, Addison's disease, autoimmune thyroid disease and/or Type 1 diabetes.
  • ||||||||||  methimazole / Generic mfg.
    A Rare case of Methimazole induced Grave Agranulocytosis (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2116;    
    The mechanism behind is both immune-mediated toxicity and direct toxicity from oxidative process mediated by myeloperoxidase and cytochrome P450 enzymes. Agranulocytosis caused by ATD is usually dose dependent and mostly present with significant hyperthyroid state.
  • ||||||||||  methimazole / Generic mfg., dexamethasone / Generic mfg., propranolol / Generic mfg.
    HCG-Induced and Autoimmune Hyperthyroidism in a Male Patient with HCG Secreting Germ Cell Tumor (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2114;    
    The interplay between HCG thyrotropic effects and thyroid autoimmunity can be challenging and use of both binding and functional bioassays maybe helpful. Close thyroid function monitoring and frequent adjustment of thioamides are needed as patients undergo treatment of the primary HCG source as well as long term follow up.